MetaCap

Novavax Statistics

NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

7.47-0.25 (-3.24%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Novavax by the numbers

Novavax has a market capitalization of $1.23 billion based on 165.01M shares outstanding. With trailing EPS of $-0.52, Novavax is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 27.8% below its 50-day average and 19.8% below its 200-day average.

Average daily trading volume is 6.67M shares, or about $49.8 million in dollar volume.

Summary generated from market data by MetaCap's automated system. Methodology

NVAX valuation vs. peer median

NVAX compared with the median of 8 peer companies
MetricNVAXPeer medianDifference
Market cap$1.23B$1.39B-11%
Avg. volume6.67M698.28K+855%

Peer median across 8 companies: TSHA, VOR, IMCR, MESO, INBX, WWB, ALVO, RXRX.

Valuation

Price / sales (latest FY)
1.10
EPS (TTM)
$-0.52

Price and trading

Previous close
7.72
Open
7.59
Day range
7.43 – 7.98
52-week range
6.36 – 13.39
52-week change
+15.46%
Beta
—
Volume
4.73M

Dividends and events

Annual dividend
None

Additional statistics

Market Cap
1.23B
Forward Pe
-41.50
Eps
-0.52
Dividend Yield
0.00%
Dividend Rate
0.00
Week52 High
13.39
Week52 Low
6.36
Avg Volume
6.67M
Shares Outstanding
165.01M
Ma50
10.34
Ma200
9.32
Earnings Date
Nov 5, 2026
Pct From52w High
-44.21%
Pct From52w Low
17.45%

Related